{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000014","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.965596+00:00","generated_at":"2026-05-27T08:21:37.414540+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%","bullets":["Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.","Cash and marketable securities $609.6M as of Nov 30, 2024, up from $295.3M a year earlier.","NX-5948 achieved 75.5% objective response rate in r/r CLL/SLL; received FDA Fast Track and EMA PRIME designations.","Appointed John Northcott as Chief Commercial Officer in January 2025.","Plans to commence registration trials for NX-5948 in CLL and explore autoimmune indications in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000014","json":"https://secwatch.observer/filing/0001549595-25-000014.json","markdown":"https://secwatch.observer/filing/0001549595-25-000014.md","text":"https://secwatch.observer/filing/0001549595-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/0001549595-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/nrix-20250128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:21:37.414540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}